Lidexa
PrescriptionNoms de marque : Lidexa
About This Medication
DESCRIPTION Lidexa™ (Lidocaine Hydrochloride) Cream 38.8
Principes Actifs
| Ingrédient | Dosage |
|---|---|
| Lidocaine | - |
Indications et Utilisation
Posologie et Administration
Side Effects Overview
Mises en Garde et Précautions
WARNINGS For external use only. Not for ophthalmic use. Avoid contact with eyes. Excessive application may result in increased systemic absorption. Keep out of reach of children.
Contre-indications
CONTRAINDICATIONS Lidexa™ is contraindicated in patients with known hypersensitivity to lidocaine or any component of the formulation.
Frequently Asked Questions
INDICATIONS AND USAGE Lidexa™ is indicated for topical analgesia as directed by a healthcare provider.
DOSAGE AND ADMINISTRATION For topical use only. Apply to the affected area 3 to 4 times daily or as directed by a healthcare provider.
WARNINGS For external use only. Not for ophthalmic use. Avoid contact with eyes. Excessive application may result in increased systemic absorption. Keep out of reach of children.
CONTRAINDICATIONS Lidexa™ is contraindicated in patients with known hypersensitivity to lidocaine or any component of the formulation.
Lidexa is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Topical Products
Browse all Topical products →References & Data Sources
- • DailyMed — Lidexa drug label (National Library of Medicine)
- • openFDA — Lidexa label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 1723991 (NLM Normalized Drug Names)
- • NDC Directory — Lidexa (FDA National Drug Code)
Avertissement Médical
Les informations sur cette page sont destinées à des fins éducatives uniquement et ne doivent pas être utilisées en remplacement d'un avis médical professionnel, d'un diagnostic ou d'un traitement.
Consultez toujours votre médecin ou tout autre professionnel de santé qualifié pour toute question relative à une condition médicale ou à un médicament.
Sources des données : DailyMed (NLM), openFDA, MFDS